Real Exam Questions/Answers of 351-080

Killexams Updated 351-080

Complete examcollection is provided Here   |   View Vendors, Tracks Home

351-080 - CCIE Data Center Written (Beta) - BrainDump Information

Vendor Name : Cisco
Exam Code : 351-080
Exam Name : CCIE Data Center Written (Beta)
Questions and Answers : 120 Q & A
Updated On : November 9, 2018
PDF Download Mirror : 351-080 Braindumps
Get Full Version : Killexams 351-080 Full Version


Guarantee your prosperity with this 351-080 question bank


We have our specialists working constantly for the social event of actual exam questions of 351-080. All the pass4sure questions and answers of 351-080 collected by our group are verified on and progressive by method for our 351-080 authorized team. We keep on identified with the competitors appeared to be inside the 351-080 exam to get their surveys around the 351-080 test, we get 351-080 exam proposals and insights, their delight in about the strategies utilized inside the actual 351-080 exam, the blunders they finished in the actual test after which enhance our material in this way. When you experience our pass4sure questions and answers, you will detect guaranteed around the majority of the themes of test and experience that your skill has been altogether moved forward. These pass4sure questions and answers are not simply practice questions, these are real exam questions and answers sufficient to pass the 351-080 exam in the first attempt.

Cisco certifications are entirely required all through IT organizations. HR supervisors choose candidates who not least difficult have a skill of the subject, but rather having completed certification tests inside the subject. All the Cisco certifications outfitted on Pass4sure are normal global.

Is it accurate to say that you are searching for pass4sure actual exams questions and answers for the CCIE Data Center Written (Beta) exam? We are ideal here to offer you one most updated and extraordinary resources is killexams.com. They have assembled a database of questions from actual exams for you to assemble and pass 351-080 exam on the first attempt. All training materials on the killexams.com site are state-of-the-art and certified by methods for guaranteed professionals.

Why killexams.com is the Ultimate decision for certification direction?

1. A quality item that Help You Prepare for Your Exam:

killexams.com is the end preparing hotspot for passing the Cisco 351-080 exam. We have deliberately consented and collected actual exam questions and answers, fully informed regarding indistinguishable recurrence from actual exam is updated, and evaluated by methods for industry experts. Our Cisco certified professionals from several gatherings are skilled and qualified/authorized individuals who've surveyed each question and answer and clarification area all together that will enable you to catch the thought and pass the Cisco exam. The charming way to plan 351-080 exam isn't perusing a printed content digital book, anyway taking activity real questions and data the proper arrangements. Practice questions help set you up until further notice not best the thoughts, anyway moreover the approach wherein questions and answer choices are exhibited over the span of the real exam.

2. Easy to use Mobile Device Access:

killexams.com give greatly easy to understand access to killexams.com items. The awareness of the site is to offer precise, up and coming, and to the guide fabric toward enable you to examine and pass the 351-080 exam. You can quick get the actual questions and arrangement database. The site is cell lovely to allow take a gander at all over, insofar as you have net association. You can simply stack the PDF in portable and concentrate all over the place.

3. Access the Most Recent CCIE Data Center Written (Beta) Real Questions and Answers:

Our Exam databases are every now and again progressive for the span of the yr to incorporate the cutting edge actual questions and answers from the Cisco 351-080 exam. Having Accurate, appropriate and bleeding edge real exam questions, you'll pass your exam on the first endeavor!

4. Our Materials is Verified through killexams.com Industry Experts:

We are doing battle to providing you with revise CCIE Data Center Written (Beta) exam questions and answers, with reasons. We make the cost of your chance and cash, the reason each question and answer on killexams.com has been approved by Cisco guaranteed specialists. They are especially guaranteed and ensured individuals, who've numerous long periods of master appreciate identified with the Cisco exams.

5. We Provide all killexams.com Exam Questions and Include Detailed Answers with Explanations:

killexams.com Huge Discount Coupons and Promo Codes are as under;
WC2017: 60% Discount Coupon for all exams on website
PROF17: 10% Discount Coupon for Orders greater than $69
DEAL17: 15% Discount Coupon for Orders greater than $99
OCTSPECIAL: 10% Special Discount Coupon for All Orders


Not at all like a wide range of exam prep sites, killexams.com gives not best updated actual Cisco 351-080 exam questions, yet in addition particular answers, references and outlines. This is fundamental to help the hopeful now not best perceive a suitable answer, but rather likewise insights about the choices that have been off-base.


351-080 dumps, 351-080 Discount Coupon, 351-080 Promo Code, 351-080 vce, Free 351-080 vce, Download Free 351-080 dumps, Free 351-080 brain dumps, pass4sure 351-080, 351-080 practice test, 351-080 practice exam, killexams.com 351-080, 351-080 real questions, 351-080 actual test, 351-080 PDF download, Pass4sure 351-080 Download, 351-080 help, 351-080 examcollection, Passleader 351-080, exam-labs 351-080, Justcertify 351-080, certqueen 351-080, 351-080 testking


View Full Exam »

Customer Reviews about 351-080

Testimonials Here   |   View Vendors, Tracks Home

351-080 - CCIE Data Center Written (Beta) - Reviews

Our customers are always happy to give their reviews about the exams. Most of them are our permanent users. They do not rely on others except our team and they get exam confidence by using our questions and answers and exam simulator.

It is unbelieveable, but 351-080 Latest dumps are availabe here.

Your 351-080 mock test papers helped me a lot in an organised and nicely dependent instruction for the examination. Thanks to you I scored 90%. The rationalization given for every answer in the mock take a look at is so precise that it gave the real revision effect to look at fabric.

Observed maximum 351-080 Questions in dumps that I prepared.

I wanted to drop you a line to thank you in your examine materials. this is the primary time ive used your cram. I just took the 351-080 today and handed with an eighty percentage rating. I have to admit that i was skeptical at the start but me passing my certification exam definitely proves it. thank you plenty! Thomas from Calgary, Canada

I need real exam questions of 351-080 exam.

I dont feel alone in the course of checks anymore because I even have a top notch take a look at partner inside the form of this killexams. Not most effective that but I also have instructors whore equipped to guide me at any time of the day. This identical steerage became given to me throughout my exams and it didnt be counted whether or not it become day or night, all my queries were responded. I am very grateful to the lecturers right here for being so excellent and pleasant and helping me in clearing my very tough exam with 351-080 study cloth and 351-080 take a look at and sure even 351-080 self examine is amazing.

Preparing 351-080 exam is matter of some hours now.

I desired to have certification in 351-080 exam and i pick killexams.com question and answer for it. the whole lot is brilliantly organized with killexams.com I used it for topics like statistics gathering and desires in 351-080 examination and i were given89 rating trying all the query and it took me nearly an hour and 20 mins. huge thanks to killexams.

Very comprehensive and proper Q&A of 351-080 examination.

Felt very proud to complete answering all questions during my 351-080 examination. Frankly talking, I owe this achievement to the question & answer by killexams.Com The material blanketed all the related inquiries to eachsubject remember and furnished the solutions in quick and unique manner. Knowledge the contents have come to be clean and memorizing became no trouble the least bit. I used to be also lucky enough to get most of the questions from the guide. Happy to bypass satisfactorily. Wonderful killexams

351-080 Questions and Answers required to pass the certification exam at first attempt.

This is to inform that I passed 351-080 exam the other day. This killexams.com questions answers and exam simulator was very useful, and I dont think I would have done it without it, with only a week of preparation. The 351-080 questions are real, and this is exactly what I saw in the Test Center. Moreover, this prep corresponds with all the key issues of the 351-080 exam, so I was fully prepared for a few questions that were slightly different from what killexams.com provided, yet on the same topic. However, I passed 351-080 and happy about it.

it is exquisite to have 351-080 real exam questions.

I handed, and honestly delighted to record that Killexams adhere to the claims they make. They provide actualexamination questions and the sorting out engine works perfectly. The package deal includes the whole thing they promise, and their customer service works nicely (I had to get in contact with them on the grounds that first my on line rate could not undergo, however it grew to become out to be my fault). Anyhow, that may be a very good product, an entire lot higher than I had predicted. I passed 351-080 examination with nearly pinnacle score, some thing I in no way notion i used for you to. Thanks.

it is fine idea to memorize those 351-080 modern dumps.

This coaching kit has helped me bypass the examination and emerge as 351-080 certified. I could not be greater excited and grateful to Killexams for such an clean and dependable preparation device. I can confirm that the questions within the package are actual, this is not a faux. I selected it for being a dependable (advocated by using a pal) manner to streamline the exam training. Like many others, I could not afford reading full time for weeks or even months, and Killexams has allowed me to squeeze down my education time and still get a terrific result. Great solution for busy IT experts.

No greater worries while making ready for the 351-080 examination.

One in every of maximum complex task is to choose extremely good examine cloth for 351-080 certification exam. I neverhad enough religion in myself and therefore idea I wouldnt get into my preferred university due to the fact I didnt have enough things to have a have a look at from. This killexams.Com came into the photo and my mindset changed. I used so one can get 351-080 fully prepared and that i nailed my check with their assist. Thanks.

blessings of 351-080 certification.

A few specific guys cant deliver an alteration to the worlds way however they might only assist you to understand whether or notyouve were given been the best man who knew the way to do that and i want to be recounted in this global and make my non-public mark and i have been so lame my entire manner but I understand now that I preferred to get a bypassin my 351-080 and this can make me well-known possibly and sure i am brief of glory however passing my A+ assessments with killexams.Com changed into my morning and night time time glory.

View Practice Questions »

See more Cisco exam dumps

Direct Downloads Here   |   View Vendors, Latest Home

Real Exam Questions and Answers of exams

We offer a huge collection of Cisco exam questions and answers, study guides, practice exams, Exam Simulator.

642-545 | 600-511 | 9E0-851 | 650-304 | 600-199 | 650-296 | 650-299 | 700-701 | 500-205 | 700-505 | 648-266 | 700-001 | 650-155 | 500-452 | 650-328 | 640-692 | 650-312 | 642-132 | 650-286 | 300-210 | 642-736 | 500-275 | 300-101 | 650-159 | 640-461 | 840-425 | 700-551 | 350-023 | 650-126 | 642-979 | 650-059 | 650-293 | 642-242 | 650-195 | 300-075 | 642-457 | 650-322 | 642-241 | 500-451 | 650-752 | 650-968 | 642-741 | 646-985 | 642-447 | 642-278 | 700-302 | 600-210 | 650-294 | 642-467 | 700-702 |

View Complete Cisco Collection »

Latest Exams added

Recently Updated Here   |   View Vendors, Latest Home

Latest Real Exam Questions and Answers Added to Killexams.com

We keep our visitors and customers updated regarding the latest technology certifications by providing reliable and authentic exam preparation material. Our team remain busy in updating 351-080 exam training material as well as reviewing the real exam changes. They try best to provide each and every relevant information about the test for the candidate to get good marks and come out of test center happily.

1Z0-628 | 1Z0-934 | 1Z0-974 | 1Z0-986 | 202-450 | 500-325 | 70-537 | 70-703 | 98-383 | 9A0-411 | AZ-100 | C2010-530 | C2210-422 | C5050-380 | C9550-413 | C9560-517 | CV0-002 | DES-1721 | MB2-719 | PT0-001 | CPA-REG | CPA-AUD | AACN-CMC | AAMA-CMA | ABEM-EMC | ACF-CCP | ACNP | ACSM-GEI | AEMT | AHIMA-CCS | ANCC-CVNC | ANCC-MSN | ANP-BC | APMLE | AXELOS-MSP | BCNS-CNS | BMAT | CCI | CCN | CCP | CDCA-ADEX | CDM | CFSW | CGRN | CNSC | COMLEX-USA | CPCE | CPM | CRNE | CVPM | DAT | DHORT | CBCP | DSST-HRM | DTR | ESPA-EST | FNS | FSMC | GPTS | IBCLC | IFSEA-CFM | LCAC | LCDC | MHAP | MSNCB | NAPLEX | NBCC-NCC | NBDE-I | NBDE-II | NCCT-ICS | NCCT-TSC | NCEES-FE | NCEES-PE | NCIDQ-CID | NCMA-CMA | NCPT | NE-BC | NNAAP-NA | NRA-FPM | NREMT-NRP | NREMT-PTE | NSCA-CPT | OCS | PACE | PANRE | PCCE | PCCN | PET | RDN | TEAS-N | VACC | WHNP | WPT-R | 156-215-80 | 1D0-621 | 1Y0-402 | 1Z0-545 | 1Z0-581 | 1Z0-853 | 250-430 | 2V0-761 | 700-551 | 700-901 | 7765X | A2040-910 | A2040-921 | C2010-825 | C2070-582 | C5050-384 | CDCS-001 | CFR-210 | NBSTSA-CST | E20-575 | HCE-5420 | HP2-H62 | HPE6-A42 | HQT-4210 | IAHCSMM-CRCST | LEED-GA | MB2-877 | MBLEX | NCIDQ | VCS-316 | 156-915-80 | 1Z0-414 | 1Z0-439 | 1Z0-447 | 1Z0-968 | 300-100 | 3V0-624 | 500-301 | 500-551 | 70-745 | 70-779 | 700-020 | 700-265 | 810-440 | 98-381 | 98-382 | 9A0-410 | CAS-003 | E20-585 | HCE-5710 | HPE2-K42 | HPE2-K43 | HPE2-K44 | HPE2-T34 | MB6-896 | VCS-256 | 1V0-701 | 1Z0-932 | 201-450 | 2VB-602 | 500-651 | 500-701 | 70-705 | 7391X | 7491X | BCB-Analyst | C2090-320 | C2150-609 | IIAP-CAP | CAT-340 | CCC | CPAT | CPFA | APA-CPP | CPT | CSWIP | Firefighter | FTCE | HPE0-J78 | HPE0-S52 | HPE2-E55 | HPE2-E69 | ITEC-Massage | JN0-210 | MB6-897 | N10-007 | PCNSE | VCS-274 | VCS-275 | VCS-413 |

View Recently Added Exams »

See more dumps

Direct Downloads Here   |   View Vendors, Latest Home

Real Exam Questions and Answers of exams

Here are some exams that you can explore by clicking the link below. There are thousands of exams that we provide to our candidates covering almost all the areas of certifications.

000-883 | 000-965 | 000-N27 | 9L0-505 | 201-450 | HP0-D17 | 70-338 | 1Z0-468 | JN0-201 | HP0-T01 | 000-512 | A00-201 | E20-330 | 000-130 | HP0-S28 | 000-904 | HP0-390 | 156-915-80 | C2180-529 | HPE0-J76 | PT0-001 | 920-548 | 3600-1 | M2020-733 | 212-055 | C2140-135 | HP3-025 | 70-735 | 9A0-059 | 920-166 | 190-737 | 2B0-011 | P2090-050 | 00M-653 | C2050-725 | 650-312 | 920-450 | A2040-408 | 000-866 | E20-655 | 920-330 | IBQH001 | 1Z0-462 | C2020-632 | HP2-H40 | C2140-056 | 400-351 | HP3-C17 | 0B0-410 | 70-703 |

View Practice Questions »

Top of the list Vendors

Certification Vendors Here   |   View Exams, Latest Home

Industry Leading Vendors

Top notch vendors that dominate the entire world market by their technology and experties. We try to cover almost all the technology vendors and their certification areas so that our customers and visitors obtain all the information about test at one place.

RSA | See-Beyond | Symantec | GIAC | Cloudera | SUSE | P&C | Intel | NetworkAppliance | iSQI | Network-General | Nokia | NCLEX | IELTS | NI | AppSense | CWNP | Foundry | FSMTB | GRE | NCIDQ | HRCI | CSP | Tibco | Riverbed | Dassault | GuidanceSoftware | NCEES | APA | SNIA | The-Open-Group | CA-Technologies | Palo-Alto | Fujitsu | PEOPLECERT | TruSecure | Pegasystems | OMG | IBQH | SAP | Social-Work-Board | APICS | HR | VCE | ASQ | Veeam | LSI | Sun | NVIDIA | NIELIT |

View Practice Questions »

Sample Real Exam Questions/Answers

Certification Vendors Here   |   View Exams, Latest Home

351-080 Demo and Sample

Note: Answers are below each question.
Samples are taken from full version.

Pass4sure 351-080 dumps | Killexams.com 351-080 real questions | [HOSTED-SITE]



Killexams.com 351-080 Dumps and Real Questions

100% Real Questions - Exam Pass Guarantee with High Marks - Just Memorize the Answers



351-080 exam Dumps Source : CCIE Data Center Written (Beta)

Test Code : 351-080
Test Name : CCIE Data Center Written (Beta)
Vendor Name : Cisco
Q&A : 120 Real Questions

these 351-080 actual test questions works within the actual take a look at.
Authentic brain dumps, everything you get there is fully reliable. I heard good reviews on killexams.com, so I purchased this to prepare for my 351-080 exam. Everything is as good as they promise, good quality, smooth practice exam. I passed 351-080 with 96%.


What are requirements to pass 351-080 exam in little effort?
i am ranked very excessive amongst my magnificence buddies on the listing of extraordinary students however it besthappened after I registered in this killexams.com for a few exam assist. It turned into the high ranking analyzing programin this killexams.com that helped me in joining the excessive ranks at the side of other extraordinary students of my class. The assets on this killexams.com are commendable due to the fact theyre unique and extremely useful for preparationthru 351-080, 351-080 dumps and 351-080 books. im glad to put in writing those phrases of appreciation due to the fact this killexams.com merits it. thanks.


Weekend take a look at is enough to skip 351-080 examination with Q&A I were given.
i am over the moon to mention that I exceeded the 351-080 exam with ninety two% rating. killexams.com Questions & answers notes made the entire issue substantially easy and clean for me! maintain up the notable work. inside the wake of perusing your direction notes and a chunk of practice structure exam simulator, i used to be efficiently ready to bypass the 351-080 examination. clearly, your direction notes in reality supported up my actuality. a few topics like instructor conversation and Presentation abilties are achieved very nicely.


You simply need a weekend to prepare 351-080 examination with these dumps.
A few tremendous news is that I exceeded 351-080 check the day past... I thank whole killexams.Com institution. I certainly respect the amazing paintings that you All do... Your schooling cloth is notable. Maintain doing appropriate paintings. I will actually use your product for my next exam. Regards, Emma from the large apple


prepare these questions otherwise Be prepared to fail 351-080 examination.
I wanted to have certification in test 351-080 and i get it with killexams. Perfect pattern of new modules facilitate me to attempt all the 38 questions inside the given time-body. I score more than 87. I actually have to mention that I may want to in no way ever have carried out it on my own what i used which will accumulate with killexams.Com Q&A. Killexams.Com Q&A offer the ultra-present day module of questions and cover the associated subjects. Thanks to killexams.Com Q&A.


a way to put together for 351-080 examination?
Ive passed the 351-080 examination with this! This is the number one time I used killexams.com, but now I realise its now not gonna be the last one! With the workout checks and actual questions, taking this examination have become relatively clean. That could be a extremely good way to get certified - which are not some thing like something else. If youve been through any in their exams, youll realise what I advise. 351-080 is difficult, but killexams.com is a blessing!


found an real source for actual 351-080 examination questions.
Have surpassed 351-080 examination with killexams.Com questions answers. Killexams.Com is a hundred% reliable, maximum of the questions had been similar to what I have been given on the exam. I missed a few questions just due to the fact I went smooth and didnt do not forget the solution given inside the set, but considering the reality that I got the rest proper, I handed with right rankings. So my recommendation is to examine the whole lot you get in your coaching %. From killexams.Com, that is all you want to skip 351-080.


Stop worrying anymore for 351-080 test.
that is an without a doubt valid and dependable resource, with actual 351-080 questions and accurate answers. The checking out engine works very smooth. With extra info and suitable customer support, this is an incredibly desirable provide. No free random braindumps available on line can examine with the fine and the coolest enjoy I had with Killexams. I exceeded with a virtually excessive score, so Im telling this primarily based on my private experience.


pleased to concentrate that dumps modern day 351-080 examination are available proper here.
I missed multiple inquiries most effective for the reason that I went clean and didnt recall the answer given inside the unit, however given that I got the relaxation right, I handed and solved forty three/50 questions. So my advice is to research all that I get from killexams.Com Q&A - that is the entirety I need to pass. I handed this exam due to killexams. This percent is one hundred% trustworthy, a massive part of the inquiries were the same as what I were given at the 351-080 exam.


No questions was asked that was out of these Q&A bank.
killexams.com is the exceptional IT exam practise I ever came across: I passed this 351-080 examination without problems. Not best are the questions actual, however theyre based the manner 351-080 does it, so its very smooth to bear in mind the solution whilst the questions arise during the exam. Not all of them are one hundred% equal, however many are. The rest is simply very similar, so if you have a look at the killexams.com substances nicely, youll have no problem sorting it out. Its very cool and useful to IT professionals like myself.


Cisco Cisco CCIE Data Center

Cisco Readies 400G community Switches for information centers | killexams.com Real Questions and Pass4sure dumps

Cisco on Wednesday introduced its first set of 400G statistics center network switches aimed at assuaging the bandwidth needs of hyperscale cloud businesses, colossal corporations, and repair providers. 

both new Cisco Nexus 3400-S switches are for hyperscalers with high-bandwidth wants for issues like video streaming, whereas both new Nexus 9000 switches are for top-conclusion firms taking competencies of artificial intelligence and desktop studying and service providers building 5G networks, Thomas Scheibe, VP of product administration for Cisco facts core Switching, told statistics center expertise.

These subsequent-technology 400G (Gigabit Ethernet) switches have 4 times extra throughput than the networking large’s current 100G offerings. Cisco expects to ship them in the first half of 2019.

“We believe 400GbE is the next frontier,” Scheibe mentioned. “a hundred gig has been reality for 3 years, and four hundred gig is ready to develop into fact.”

network gadget vendors are all racing to deliver their 400G information middle switches to market. Arista Networks announced plans for its first 400G switches ultimate week, while Juniper Networks launched particulars of its forthcoming 400GbE switches in July. Cisco, for its part, in the past verified its 400GbE change expertise this past summer time.

Cisco

The Cisco Nexus 3432D 400GbE swap

“everyone who sells to hyperscalers – no matter if that be Cisco, Juniper, Arista, or the white-box ODMs – will should have 400GbE data core switches of their portfolio in 2019,” Brad Casemore, IDC’s VP for data middle networks, instructed data core skills. “There’s in fact no option, and that’s why you’ve viewed a succession of 400GbE announcements from Juniper, Arista, and Cisco respectively. From a earnings standpoint, they will all attain market at in regards to the equal time, but no person desires to get outmaneuvered by using a competitor.”

Hyperscalers have been the basic drivers for 400G demand, he observed. however different segments of the market, including telecommunications carrier suppliers rolling out 5G networks and excessive-conclusion organizations in verticals corresponding to monetary features, will also undertake the technology.

“Hyperscalers should be first, and they'll purchase within the premier volumes, creating the form of economies of scale with a purpose to make 400G more within your means for subsequent buyers,” Casemore spoke of.

Scheibe from Cisco is of the same opinion, saying there's pent-up demand among the many largest cloud suppliers. “all the very big cloud providers will go into trials the first half of 2019, and in one form or another they're going to birth deploying a 400GbE network in the 2nd half of 2019,” he spoke of.

On the enterprise front, Scheibe said, early adopters of 400G switches may be corporations in verticals reminiscent of healthcare, insurance, and financial functions that want quicker facts middle networks to greater directly operate records analytics the usage of artificial intelligence or desktop discovering.

amongst service suppliers, telecommunications organizations will use the 400G switches to construct area records facilities as they build out their 5G networks, he pointed out. so that you can allow the service providers to supply quicker service to their shoppers, while featuring high efficiency in a small footprint.

“They want a compact community solution at the area,” Scheibe said.

the new Cisco 400G Switches

Cisco’s two new Nexus 3400-S switches for hyperscale organizations might be purchasable for client evaluations in December. The Nexus 3432D-S swap is a 1RU swap that presents 32 400G ports, while the Nexus 3408-S switch facets an eight-slot 4RU chassis that makes it possible for for a mix of 100G to 400G connections. both feature a single 12.8Tbps chip with a 70MB buffer.

Cisco

The Cisco Nexus 93600CD 400GbE switch

both new Nexus 9300-GX switches for colossal businesses and service providers will be available for client reviews all over the first quarter of 2019. The Nexus 9316D-GX is a 1RU backbone change with 16 400G ports, while the Nexus 93600CD-GX is a 1RU leaf swap with 28 100G ports and eight 400G ports.

the entire 400G switches are flexible and allow records middle operators to “break out” a port and use smaller 10G, 25G, 40G, 50G, and 100G connections, Scheibe says.

Cisco

The Cisco Nexus 9316D 400GbE switch

Intent-primarily based Networking help

based on him, Cisco rises above its competitors as a result of its switches no longer only supply quicker community speeds but additionally true-time visibility into network packets, flows, and pursuits. That makes it possible for for more suitable security, automation, visibility, and analytics, he talked about.

the brand new Nexus 9300-GX switches utterly helps Cisco’s intent-primarily based networking (IBN) items: software Centric Infrastructure (ACI), Cisco’s data center application-defined networking offering which offers intent via policy-based mostly automation; the Tetration Platform, which makes use of algorithms to analyze the network in actual-time and detects community and protection problems; and network Assurance Engine (NAE), software that verifies community habits and ensures the community is in compliance with policies and may take corrective action. the brand new Nexus 3400-S switches deliver one of the vital IBN capabilities, he referred to.

See also: Intent-based Networking within the information center: Cisco vs. Juniper


CCIE : ITD and rise in CCIE information middle | killexams.com Real Questions and Pass4sure dumps

ITD and rise are now a part of CCIE data middle:

https://learningnetwork.cisco.com/neighborhood/certifications/ccie_data_center/written-examination-v2/exam-topics

intelligent traffic Director (ITD) is a hardware based multi-terabit layer four load-balancing, site visitors guidance and services insertion answer on the Nexus 5k/6k/7k/9k series of switches.

area Written examination (%) Lab examination (%)   1.0 Cisco facts core L2/L3 applied sciences 24% 27% show details 2.0 Cisco information center network amenities12% 13% hide details 2.1 Design, implement and Troubleshoot provider Insertion and Redirection
  • 2.1.a Design, implement and Troubleshoot service Insertion and Redirection as an example LB, vPATH, ITD, upward push
  • 2.2 Design, enforce and Troubleshoot community functions

  • 2.2.a Design, enforce and Troubleshoot community capabilities as an example policy drivenL4-L7 features
  • three.0 facts center Storage Networking and Compute 23% 26% display details 4.0 facts core Automation and Orchestration 13% 14% demonstrate details 5.0 information center cloth Infrastructure 18% 14% display details 6.0 Evolving applied sciences 10% N/A demonstrate details

    To study upward thrust (faraway built-in services Engine), please see: http://www.cisco.com/go/rise

    To learn about ITD (intelligent site visitors Director), please see: http://www.cisco.com/go/itd

    http://blogs.cisco.com/datacenter/itd-load-balancing-site visitors-guidance-clustering-the usage of-nexus-5k6k7k9k


    Cisco u.s.the ante for 400G Ethernet with big-bandwidth facts-center switches | killexams.com Real Questions and Pass4sure dumps

    Cisco is bringing excessive-pace Ethernet to the facts middle with 4 new switches it says will eventually turn into the foundation of excessive-density, intent-primarily based networks.

    the new 400G Ethernet switches fall into two camps, two boxes within the Nexus 9000 household aimed at big-commercial enterprise community valued clientele and two within the 3400-S classification targeted at excessive-bandwidth hyperscale clients. These switches pave the manner for Terabit Ethernet switching to become a mainstream know-how, wrote Thomas Scheiberote, Cisco vice chairman of product administration, records core Networking.

    The Cisco announcement is the third 400G Ethernet swap pronouncement in the past few months – this summer time Juniper made a large-ranging dedication to the technology, and in October Arista joined the march with switches in a position to helping 400G speeds – both aimed toward hyperscale cloud and statistics-center networks.

    "The 400G timeline should be pushed mainly by way of when the optics for the expertise are available in scale and cost," referred to Sameh Boujelbene, senior director at Dell’Oro. "We see a small ramp up in 2019 – notwithstanding i'd also expect to hear much more from Cisco, Arista and Juniper subsequent 12 months – however then 400G ports will more than triple in the 2020 timeframe."

    Cisco says 400G will let webscale shoppers, information-core and 5G-mobile operators create extra powerful networks more can charge-without difficulty whereas offering clients with four instances the bandwidth and scale of existing networks.

    The bandwidth and scale mandatory for 400G is obvious, Cisco says, because:

  • There may be 20 billion to 30 billion on-line IoT gadgets on earth through this decade.
  • clients will personal greater than 25 million 5G-able contraptions through 2021 and greater than eighty p.c of all IP site visitors might be bandwidth-hungry, latency-sensitive video content material.
  • by 2021 hyperscale statistics centers will grow from 338 in quantity at the conclusion of 2016 to 628, representing fifty three p.c of all installed information-middle servers by way of 2021.
  • commercial enterprise clients may well be most drawn to the two new Nexus 9300GX boxes, which Cisco says expand its overarching application Centric Infrastructure (ACI) and its intent-primarily based networking statistics-center designs, which in actual time can identify and react to altering network situations. 

    ACI brings with it help for Cisco items such as the Tetration Analytics platform, which collects all manner of  telemetry information from Cisco and non-Cisco instruments on the network. The system then uses computing device studying and conduct analysis to provide network administrators a more suitable figuring out and manage of their information-center elements.

    for instance, Cisco noted Tetration offers shoppers a single device to bring together consistent safety telemetry throughout the entire data middle and analyze giant volumes of data in actual time. In a multi-cloud enterprise, Tetration can lock down tens of millions of whitelist policy entries across hundreds of functions.

    a different key component is Cisco’s community Assurance Engine (NAE) application, which verifies intent-based network habits and ensures intentions were translated into policies and orchestrated right through the network.

    “The strategy Cisco is taking with these switches – emphasizing application aspects over the speed of the box is basically new for them, however also




    Killexams.com 351-080 Dumps and Real Questions

    100% Real Questions - Exam Pass Guarantee with High Marks - Just Memorize the Answers



    351-080 exam Dumps Source : CCIE Data Center Written (Beta)

    Test Code : 351-080
    Test Name : CCIE Data Center Written (Beta)
    Vendor Name : Cisco
    Q&A : 120 Real Questions

    these 351-080 actual test questions works within the actual take a look at.
    Authentic brain dumps, everything you get there is fully reliable. I heard good reviews on killexams.com, so I purchased this to prepare for my 351-080 exam. Everything is as good as they promise, good quality, smooth practice exam. I passed 351-080 with 96%.


    What are requirements to pass 351-080 exam in little effort?
    i am ranked very excessive amongst my magnificence buddies on the listing of extraordinary students however it besthappened after I registered in this killexams.com for a few exam assist. It turned into the high ranking analyzing programin this killexams.com that helped me in joining the excessive ranks at the side of other extraordinary students of my class. The assets on this killexams.com are commendable due to the fact theyre unique and extremely useful for preparationthru 351-080, 351-080 dumps and 351-080 books. im glad to put in writing those phrases of appreciation due to the fact this killexams.com merits it. thanks.


    Weekend take a look at is enough to skip 351-080 examination with Q&A I were given.
    i am over the moon to mention that I exceeded the 351-080 exam with ninety two% rating. killexams.com Questions & answers notes made the entire issue substantially easy and clean for me! maintain up the notable work. inside the wake of perusing your direction notes and a chunk of practice structure exam simulator, i used to be efficiently ready to bypass the 351-080 examination. clearly, your direction notes in reality supported up my actuality. a few topics like instructor conversation and Presentation abilties are achieved very nicely.


    You simply need a weekend to prepare 351-080 examination with these dumps.
    A few tremendous news is that I exceeded 351-080 check the day past... I thank whole killexams.Com institution. I certainly respect the amazing paintings that you All do... Your schooling cloth is notable. Maintain doing appropriate paintings. I will actually use your product for my next exam. Regards, Emma from the large apple


    prepare these questions otherwise Be prepared to fail 351-080 examination.
    I wanted to have certification in test 351-080 and i get it with killexams. Perfect pattern of new modules facilitate me to attempt all the 38 questions inside the given time-body. I score more than 87. I actually have to mention that I may want to in no way ever have carried out it on my own what i used which will accumulate with killexams.Com Q&A. Killexams.Com Q&A offer the ultra-present day module of questions and cover the associated subjects. Thanks to killexams.Com Q&A.


    a way to put together for 351-080 examination?
    Ive passed the 351-080 examination with this! This is the number one time I used killexams.com, but now I realise its now not gonna be the last one! With the workout checks and actual questions, taking this examination have become relatively clean. That could be a extremely good way to get certified - which are not some thing like something else. If youve been through any in their exams, youll realise what I advise. 351-080 is difficult, but killexams.com is a blessing!


    found an real source for actual 351-080 examination questions.
    Have surpassed 351-080 examination with killexams.Com questions answers. Killexams.Com is a hundred% reliable, maximum of the questions had been similar to what I have been given on the exam. I missed a few questions just due to the fact I went smooth and didnt do not forget the solution given inside the set, but considering the reality that I got the rest proper, I handed with right rankings. So my recommendation is to examine the whole lot you get in your coaching %. From killexams.Com, that is all you want to skip 351-080.


    Stop worrying anymore for 351-080 test.
    that is an without a doubt valid and dependable resource, with actual 351-080 questions and accurate answers. The checking out engine works very smooth. With extra info and suitable customer support, this is an incredibly desirable provide. No free random braindumps available on line can examine with the fine and the coolest enjoy I had with Killexams. I exceeded with a virtually excessive score, so Im telling this primarily based on my private experience.


    pleased to concentrate that dumps modern day 351-080 examination are available proper here.
    I missed multiple inquiries most effective for the reason that I went clean and didnt recall the answer given inside the unit, however given that I got the relaxation right, I handed and solved forty three/50 questions. So my advice is to research all that I get from killexams.Com Q&A - that is the entirety I need to pass. I handed this exam due to killexams. This percent is one hundred% trustworthy, a massive part of the inquiries were the same as what I were given at the 351-080 exam.


    No questions was asked that was out of these Q&A bank.
    killexams.com is the exceptional IT exam practise I ever came across: I passed this 351-080 examination without problems. Not best are the questions actual, however theyre based the manner 351-080 does it, so its very smooth to bear in mind the solution whilst the questions arise during the exam. Not all of them are one hundred% equal, however many are. The rest is simply very similar, so if you have a look at the killexams.com substances nicely, youll have no problem sorting it out. Its very cool and useful to IT professionals like myself.


    Unquestionably it is hard assignment to pick dependable certification questions/answers assets regarding review, reputation and validity since individuals get sham because of picking incorrectly benefit. Killexams.com ensure to serve its customers best to its assets concerning exam dumps update and validity. The vast majority of other's sham report dissension customers come to us for the brain dumps and pass their exams joyfully and effortlessly. We never trade off on our review, reputation and quality on the grounds that killexams review, killexams reputation and killexams customer certainty is imperative to us. Uniquely we deal with killexams.com review, killexams.com reputation, killexams.com sham report objection, killexams.com trust, killexams.com validity, killexams.com report and killexams.com scam. On the off chance that you see any false report posted by our rivals with the name killexams sham report grievance web, killexams.com sham report, killexams.com scam, killexams.com protest or something like this, simply remember there are constantly awful individuals harming reputation of good administrations because of their advantages. There are a huge number of fulfilled clients that pass their exams utilizing killexams.com brain dumps, killexams PDF questions, killexams hone questions, killexams exam simulator. Visit Killexams.com, our specimen questions and test brain dumps, our exam simulator and you will realize that killexams.com is the best brain dumps site.

    [OPTIONAL-CONTENTS-2]


    000-J02 study guide | 000-782 practice test | VCS-371 free pdf download | BPM-001 free pdf | 9L0-060 questions answers | 000-M05 questions and answers | HP0-634 practice exam | C9510-319 dumps questions | C9530-001 test prep | 000-784 practice test | HP0-Y11 Practice test | HP0-775 real questions | 77-427 real questions | 70-528-VB practice questions | 310-202 exam questions | EE0-200 braindumps | A00-280 exam prep | 650-293 brain dumps | 000-651 pdf download | HP0-460 test prep |


    [OPTIONAL-CONTENTS-3]

    Just memorize these 351-080 questions before you go for test.
    Is it accurate to say that you are searching for Cisco 351-080 Dumps of real questions for the CCIE Data Center Written (Beta) Exam prep? We give most refreshed and quality 351-080 Dumps. Detail is at http://killexams.com/pass4sure/exam-detail/351-080. We have aggregated a database of 351-080 Dumps from actual exams keeping in mind the end goal to give you a chance to get ready and pass 351-080 exam on the first attempt. Simply remember our Q&A and unwind. You will pass the exam.

    The only issue that's in any manner very important right here is passing the 351-080 - CCIE Data Center Written (Beta) test. All that you need will be a high score of Cisco 351-080 exam. The simply a widowed facet you wish to try to is downloading braindumps of 351-080 exam confine mind directs currently. we are not letting you down as we already guaranteed the success. The professionals likewise keep step with the most up and returning test with the intention to relinquish the additional an area of updated dumps. One twelvemonth loose get right of entry to possess the aptitude to them via the date of purchase. every one could benifit price of the 351-080 exam dumps through killexams.com at an occasional value. often there will be a markdown for each body all. Are you looking for Cisco 351-080 Dumps of actual questions for the CCIE Data Center Written (Beta) test prep? we offer most updated and nice 351-080 Dumps. Detail is at http://killexams.com/pass4sure/exam-detail/351-080. we have got compiled an information of 351-080 Dumps from actual tests thus on allow you to organize and pass 351-080 exam on the first attempt. simply memorize our Q&A and relax. you will pass the test. killexams.com Discount Coupons and Promo Codes are as under; WC2017 : 60% Discount Coupon for all exams on website PROF17 : 10% Discount Coupon for Orders additional than $69 DEAL17 : 15% Discount Coupon for Orders larger than $99 SEPSPECIAL : 10% Special Discount Coupon for All Orders

    On the off chance that you are searching for 351-080 Practice Test containing Real Test Questions, you are at correct place. We have accumulated database of questions from Actual Exams with a specific end goal to enable you to plan and pass your exam on the first attempt. All preparation materials on the site are Up To Date and confirmed by our specialists.

    killexams.com give most recent and updated Practice Test with Actual Exam Questions and Answers for new syllabus of Cisco 351-080 Exam. Practice our Real Questions and Answers to Improve your knowledge and pass your exam with High Marks. We guarantee your success in the Test Center, covering every one of the points of exam and construct your Knowledge of the 351-080 exam. Pass beyond any doubt with our actual questions.

    Our 351-080 Exam PDF contains Complete Pool of Questions and Answers and Brain dumps checked and confirmed including references and explanations (where relevant). Our objective to gather the Questions and Answers isnt just to pass the exam at first attempt however Really Improve Your Knowledge about the 351-080 exam points.

    351-080 exam Questions and Answers are Printable in High Quality Study Guide that you can download in your Computer or some other gadget and begin setting up your 351-080 exam. Print Complete 351-080 Study Guide, convey with you when you are at Vacations or Traveling and Enjoy your Exam Prep. You can get to updated 351-080 Exam Q&A from your online record whenever.

    killexams.com Huge Discount Coupons and Promo Codes are as under;
    WC2017 : 60% Discount Coupon for all exams on website
    PROF17 : 10% Discount Coupon for Orders greater than $69
    DEAL17 : 15% Discount Coupon for Orders greater than $99
    OCTSPECIAL : 10% Special Discount Coupon for All Orders


    Download your CCIE Data Center Written (Beta) Study Guide instantly subsequent to purchasing and Start Preparing Your Exam Prep Right Now!

    [OPTIONAL-CONTENTS-4]


    Killexams 1Z0-531 brain dumps | Killexams CCA-410 exam prep | Killexams COG-142 VCE | Killexams CSSGB real questions | Killexams 1D0-621 test prep | Killexams 700-105 real questions | Killexams ST0-097 exam prep | Killexams JN0-730 cheat sheets | Killexams 270-131 practice exam | Killexams 920-199 test questions | Killexams 3202 braindumps | Killexams 156-915-71 practice test | Killexams C9530-410 exam questions | Killexams ST0-119 free pdf | Killexams 310-625 examcollection | Killexams 000-M94 dump | Killexams MB6-895 pdf download | Killexams HP2-Z37 cram | Killexams HP5-H07D questions and answers | Killexams 2B0-100 dumps questions |


    [OPTIONAL-CONTENTS-5]

    View Complete list of Killexams.com Brain dumps


    Killexams ASC-090 free pdf download | Killexams 3M0-600 brain dumps | Killexams 000-094 brain dumps | Killexams 000-723 braindumps | Killexams C4040-221 sample test | Killexams P2020-795 real questions | Killexams 000-968 test prep | Killexams ICDL-WINDOWS test questions | Killexams 310-015 real questions | Killexams 132-S-712.2 test prep | Killexams NCLEX-PN real questions | Killexams 300-370 dumps questions | Killexams 050-v70-CSEDLPS02 exam prep | Killexams 70-523-CSharp questions and answers | Killexams 70-475 braindumps | Killexams 000-208 free pdf | Killexams A2040-407 practice exam | Killexams 000-Z04 Practice Test | Killexams P2090-032 examcollection | Killexams CPCE practice test |


    CCIE Data Center Written (Beta)

    Pass 4 sure 351-080 dumps | Killexams.com 351-080 real questions | [HOSTED-SITE]

    Is CCIE Data Center A Valuable Certification | killexams.com real questions and Pass4sure dumps

    No result found, try new keyword!Cisco has written tests at 4 prime grades of IT course — expert, professional, associate and entry. In addition CCIE data center have some additional tests accessible at architect grades, expert and t...

    Five Prime Therapeutics, Inc. (FPRX) CEO Aron Knickerbocker on Q3 2018 Results - Earnings Call Transcript | killexams.com real questions and Pass4sure dumps

    Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Q3 2018 Earnings Conference Call November 6, 2018 4:30 PM ET

    Executives

    Heather Rowe - Senior Director of Investor Relations and Corporate Communications

    Aron Knickerbocker - Chief Executive Officer

    Helen Collins - Chief Medical Officer

    Bryan Irving - Chief Scientific Officer

    Linda Rubinstein - Interim Chief Financial Officer

    Analysts

    Nick Abbott - Wells Fargo

    Jonathan Chang - Leerink Partners

    Alex Heller - Jefferies

    Justin Burns - RBC Capital Markets

    Eric Josephs - JPMorgan

    Steve Seedhouse - Raymond James

    Operator

    Good day, ladies and gentlemen, and welcome to the Five Prime Therapeutics Third Quarter 2018 Earnings Call. As a reminder, this conference may be recorded.

    I'd now like to introduce your host for today's conference, Heather Rowe, Senior Director, Investor Relations and Corporate Communications. You may begin.

    Heather Rowe

    Good afternoon and thank you for joining us. I would like to welcome everyone to our conference call to discuss results for the third quarter 2018. We issued a press release this afternoon and also posted slides to accompany this presentation. The slides can be found under the Investor Relations section of our Web site under Events and Presentations.

    Joining me today are Aron Knickerbocker, Chief Executive Officer, Dr. Helen Collins, Chief Medical Officer; Dr. Bryan Irving, Chief Scientific Officer; and Linda Rubinstein, Interim Chief Financial Officer.

    Today's conference call will include forward-looking statements under the Private Securities Litigation Reform Act of 1995, including statements regarding our research and development programs and financial outlook. Actual results may differ from those indicated by these forward-looking statements due to numerous factors, including those discussed in the Risk Factors section of our SEC filings.

    Our expectations and assumptions could change. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our views change.

    I will now turn the call over to Aron.

    Aron Knickerbocker

    Thanks Heather. Good afternoon and thanks for joining us today to review our third quarter 2018.

    Highlights appear on Slide 3. Our teams are executing extremely well across the pipeline. The current status of which is shown on Slide four. All of our Five Prime sponsor trials are meeting or beating their original development timelines, which is a testament to the integrated efforts of our teams and our relentless focus on only pursuing high value medically important studies.

    We now have five drug candidates in the clinic that we are developing either on our own or with our collaborators. Typically our product candidates are only in class, first in class or meaningfully differentiated in other ways. We look for single agent activity or clear activity in for example tumor types that are rarely sensitive to Checkpoint inhibitors.

    Our immuno-oncology drug candidates address multiple immune cell types in the tumor microenvironment.

    I will start my review of our programs with bemarituzumab or bema our most advanced drug candidate. In the third quarter, we completed the Phase 1 safety lead-in portion of our FIGHT global registration trial and with our partner Zai Lab began the Phase 3 portion of the trial. You can see our bema market assumptions on Slide 5. We think this represents an attractive global market opportunity.

    Next is cabiralizumab or cabira, BMS' ongoing randomized forearm Phase 2 clinical trial continues to enroll. This trial is evaluating cabira and OPDIVO with and without chemotherapy as a second line treatment in patients with advanced pancreatic cancer. We have already shown that cabira and OPDIVO without any chemotherapy demonstrate deep and durable responses in patients who are receiving their median fourth line treatment for advanced pancreatic cancer. And we hope to provide even more benefit by adding chemotherapy which we know to be synergistic and preclinical models of pancreatic cancer.

    The current trial could generate data that would support a frontline and or a second line pivotal trial. And importantly BMS has opened and continues to open sites around the world including in the United States, Europe and Asia. BMS' partner in Asia, Ono has opted into the development of cabira.

    Slide 6 shows the estimated incidence of pancreatic cancer by line of therapy in the major markets. We think that commercial opportunity for cabira in pancreatic cancer is significant. We were pleased to hear BMS on their most recent earnings call mentioned cabira when expressing their sense of urgency to help patients find new treatment options. BMS referred to the cabira and OPDIVO trial in pancreatic cancer as an example of a randomized Phase 2 trial designed to isolate the impact of the new regimen.

    In this case cabira and OPDIVO as an antibody doublet or on top of chemo versus chemo alone in a setting such as pancreatic cancer. In their words, this is an example of an area that is screaming for innovation and where the market and patients are demanding new options. They made the point that this is especially true in microsatellite stable pancreatic cancer.

    BMS is also supporting several investigator sponsored trials evaluating additional combinations that include cabira. One example is a trial sponsored by UCSD and supported by Stand Up To Cancer and BMS. This trial called the GemCaN can trial is a randomized Phase 2 frontline maintenance trial to determine whether the combination of gemcitabine with cabira and OPDIVO can provide prolonged disease control in patients with advanced pancreatic cancer compared to gemcitabine alone.

    Another example is the clinical trials sponsored by the Yale Cancer Center and supported by Apexigen and BMS. This trial is evaluating Apexigen CD40 antibody in combination with cabira and OPDIVO in patients with melanoma lung cancer or renal cell carcinoma who progressed on prior anti-PD-1 or PD-L1 therapy. Beyond bema and cabira, our FPA150 and FPT155 programs also have the potential to address multiple tumor indications.

    I will start with that FPA150, which is our first-in-class antibody targeting B7H4. This target is in the same family of checkpoint molecules as PD-L1. In fact, B7H4 behaves pretty clinically a lot like PD-L1 and that it strongly inhibits T-cells. B7H4 is generating a lot of excitement in the investigator community because it's expressed in multiple cell types, multiple tumor types including tumor types that are not well served by immunotherapy today such as breast and gynecologic cancers.

    Our plan is to move as fast as possible to generate proof-of-concept and then hopefully to later stage development and we are moving quickly. In October, we initiated dosing in an exploratory basket cohort of our Phase 1a/1b clinical trial to investigate FPA150 monotherapy in patients with any cancer whose tumors over express B7H4. Our goal and trial overall is to find a dose and then to look for potential single agent activity with an initial focus on tumors that over express B7H4 and constitute large patient populations with high unmet medical need as shown on Slide 7.

    FPT155, our first-in-class CD80-Fc fusion protein is engineered to activate T cells through multiple pathways. We have opened enrollment in the Phase 1 clinical trial in Australia. Similar to FPA150, we are looking to find an FPT155 dose and then assess potential single agent activity.

    In addition, we're pleased that the first clinical candidate from our immuno-oncology research collaboration with BMS, the TIM-3 antibody designated BMS-986258 continues to advance in a Phase 1/2 trial. The candidate is a fully-human monoclonal antibody targeting TIM-3 and immune checkpoint receptor that is known to limit the duration and magnitude of T cell responses. BMS' TIM-3 abstract poster number p684 will be presented at the SITC conference later this week.

    As you can see our pipeline is advancing and building momentum. We're moving fast with our portfolio of mechanistically distinct product candidates. We are systematically engaging cells in the tumor microenvironment beta tumor cells, T cells, macrophages or natural killer cells. We have later stage programs that have already demonstrated their activity as well as exciting new first-in-class agents in early clinical development. And we have a strong balance sheet with no debt.

    We have increased our year-end guidance and now expect to end the year with approximately $265 million in cash and investments compared to our previous estimate of approximately $250 million.

    As we announced yesterday, I'm delighted to welcome David Smith to Five Prime as Executive Vice President and Chief Financial Officer. David brings more than 20 years of CFO and senior financial leadership experience in biotechnology. His wealth of industry and financial experience will serve Five Prime and our stakeholder as well. David will join us after Thanksgiving.

    I also want to thank Linda Rubinstein for her excellent work as Interim CFO. Having her here allowed us to be thoughtful and deliberate in our search to find the right individual for the permanent CFO role. It's been wonderful to work with her and we thank her and wish her well in her future endeavors.

    With that, I'll now turn the call over to Helen to review our clinical programs.

    Helen Collins

    Thank you, Aron.

    As Aron as highlighted we continue to make notable progress across our clinical programs. First on Slide 8 in our most advanced program bemarituzumab, our first in class FGFR2b antibody with enhanced ADCC for tumors that over express FGFR2b.

    In the third quarter, we completed the Phase 1 safety lead-in and initiated enrollment in the FIGHT trial, our randomized controlled Phase 3 global registration study. You can see the trial design on Slide 9. The FIGHT trial will evaluate bema in combination with FOLFOX6 against placebo and combination with FOLFOX6 and approximately 550 patients with advanced gastric or gastroesophageal junction cancer.

    Bema is a targeted therapy against tumors that over express FGFR2b and we are using tissue IHC or blood ctDNA tests to identify the estimated 10% of patients who are eligible for this trial. Last week, we had our U.S. investigator meeting and have heard firsthand the enthusiasm to screen patients enrolling in this trial. As you know, several therapeutic agents have failed recently in the frontline gastric cancer setting. But as we heard from the investigators bema is different from those agents because it has demonstrated single agent activity and it is an antibody targeting a selected patient population. This is most analogous to trastuzumab which was globally approved for the treatment of frontline HER 2 positive gastric cancer.

    Additionally the investigators appreciated the design of the trial with the ability to screen patients with a simple blood test of tissue samples are often limited in size or hard to track down the five trials being conducted in North America, Europe and Asia. In China where gastric cancer is common we're collaborating with Zai Lab to identify enroll patients which should shorten the overall time to complete the trial.

    An abstract featuring the Phase 1 safety lead-in chemo combination data has been accepted for a poster presentation at the ASCO GI conference in January.

    Moving on to Slide 10, cabiralizumab is our antibody to the CSF1 receptor on tumor associated macrophages. We're combining cabira CSF1R inhibition with BMS' PD-1 OPDIVO

    Last fall we presented data that demonstrated durable responses in late line patients with pancreatic cancer as shown on Slide 11. These data are unprecedented for immuno-oncology agents in pancreatic cancer in the absence of chemotherapy. Anti-PD-1 agents have not demonstrated efficacy in the approximately 98% of patients with microsatellite stable disease.

    More recently whole exome sequencing analysis has shown us that these tumors had low tumor mutations burden. In other words based on known predictive biomarkers for single agent anti-PD-1 activity these patients would not be expected to respond to OPDIVO alone.

    On the basis of this promising pulmonary data, BMS' advanced development of cabira and pancreatic cancer. Slide 12 shows their trial design. They're now enrolling patients into a second line randomized controlled Phase 2 trial of approximately 160 pancreatic cancer patients from the U.S., Canada, Europe, Japan, Korea and Taiwan.

    As Aron mentioned in their recent earnings call, BMS reiterated their urgency to find new treatment options in areas where there is high unmet need such as pancreatic cancer and use this trial as an example. This momentum is reinforced by the initiation of additional trials with cabira including the pancreatic cancer frontline maintenance trial sponsored by Stand Up to Cancer and BMS and Apexigen and BMS supported study of anti-CD40, cabira and OPDIVO in multiple solid tumors.

    Moving on to FPA150, our first-in-class B7H4 antibody is shown on Slide 13. This antibodies designed to target tumor cells through two mechanisms of action by blocking B7H4 from sending an inhibitory signal to CD80 cells and by enhancing the killing of B7H4 over expressing tumors through ADCC.

    B7H4 is a cell surface marker frequently over expressed in breast, ovarian and endometrial cancers as depicted on Slide 14.

    Moving on to Slide 15, we have an ongoing dose escalation Phase 1a study to evaluate the safety of FPA150 unselected patients. In addition, last month after clearing a dose level which may be efficacious based on our preclinical models, we opened an exploratory basket cohort of up to 10 patients whose tumors over express B7H4. We intend to investigate the potential activity of FPA150 monotherapy in these patients.

    After completing the Phase 1a dose escalation portion of the trial, we plan to initiate Phase 1b expansion portion of the trial in this portion. We will test FPA150 in various disease specific cohorts of patients whose tumors over express B7H4 such as hormone receptor positive breast, cancer triple negative breast cancer, ovarian cancer and endometrial cancer. We look forward to presenting Phase 1 data at a medical conference in 2019.

    Next is FPT155 shown on Slide 16, preclinical models suggest FPT155 has the potential to be a potent T cell co-stimulator with strong monotherapy anti-tumor activity and they also have synergistic efficacy when combined with anti-PD-1 therapy.

    Bryan will review this molecule in more detail and you'll see why we are excited that this novel product candidate is entering the clinic. We just opened enrollment for the Phase 1a/1b clinical trial for FPT155 in Australia in patients with solid tumors and plan to dose our first patients soon. Similar to FPA150, the design of this Phase 1 trial will include an exploratory cohort at a dose at which efficacy was observed in preclinical models.

    In the exploratory cohort, we will investigate FPT155 monotherapy activity in patients with solid tumors. Once the 1a dose escalation is completed we will initiate the Phase 1b expansion portion of the trial where we plan to evaluate FTT155 in various disease specific cohorts. We'll update you on the specific cancer types chosen at a future date.

    I will now turn the call over to Bryan to review our research and preclinical efforts.

    Bryan Irving

    At Five prime, we have a truly unique platform that gives us a competitive advantage to find new targets, address new cell types and ultimately develop protein therapeutics. We have multiple state-of-the-art technologies to generate monoclonal antibodies as well as other protein therapeutics such as fusion proteins. Our dynamic screening platform is helping us discover differentiated therapies that we aim to advance rapidly into clinical development and to proof-of-concept.

    One such example is FPT155. This is a first-in-class agent that we discovered by screening approximately 800 secreted and extracellular domain proteins in our library which we call the immuno. These are proteins that are expressed by immune cells or associated with immune cells and we screen them individually to identify those that inhibit tumor growth by immune dependent mechanisms.

    One of the most potent single agent proteins that we've tested is CD80. In FPT155 the CD80 extracellular domain is fused to the IgG1 Fc domain of an antibody to optimize its pharmacological and PK properties. This drug candidate does two things. First, it's the natural receptor or binding partner for CD28, the key co-stimulatory receptor needed in addition to the T cell receptor for effective activation of T cells. So by applying the CD28 [login] [ph] exogenous sleep with our drug we can modulate the degree of co-stimulation T cells received.

    Importantly we don't see super agonism with the accompanying cytokine release that we've seen with a CD28 targeted antibody. And second, FPT155 block CTLA4 from competing for endogenous CD80 allowing CD28 signaling to prevail in T cell activation. FPT155 behaves differently than CTLA4 antibodies such as Ipilimumab and tremelimumab because it interacts directly with CD28.

    We know from preclinical work in tumor-bearing mice that if we preblock CTLA4 with an antibody that lacks effective function and therefore lacks efficacy as a single agent and then we administer FP1555. FPT155 retains the majority of its activity independent of its engagement with CTLA4.

    Secondly in preclinical models FPT155 is demonstrated strong single agent activity across a wide range of single agent tumor models including the B16F10 model which is notoriously refractory to immunotherapies that include single agent anti-CTLA4 or anti-PD-1.

    So we believe this is a very different drug than anti-CTLA4 and could represent an important addition to the immuno-oncology treatment armamentarium. You can see some of our clinical results on Slide 17 and 18. We continue to fuel our pipeline and our collaborators pipeline with additional programs that are at various stages in research.

    You can see this on Slide 19, our early in vitro immuno-oncology screens included primary human effector T cells, T-RACs and macrophages. We are now optimizing screens to studying the impact of our library on the function of dendritic cells. The antigen presenting cells most adept at activating an effective anti-tumor T cell response.

    I'm excited by the platform's potentials identify novel and differentiated drug targets in this competitive, but still emerging Io space emphasizing drug targets that can lead to antibodies or other biologics that have the potential to demonstrate single agent activity.

    I will now turn the call over to Linda to review our financials.

    Linda Rubinstein

    Thank you, Bryan.

    Further details regarding our financial results can be found in the press release issued this afternoon as well as slides 20 and 21.

    We ended Q2 with a strong balance sheet cash, cash equivalents and marketable securities totaled $322 million on September 30 compared to $293 million on December 31 of last year. This increase reflects $108 million in net cash proceeds from our equity offering in January and $34.5 million in milestone and upfront payments that we've received from collaboration partners net of cash used in operations.

    Collaboration and license revenue was $5.8 million for the quarter which was less than $8.3 million for the third quarter of last year. As compared to last year, we recognized less under our cabira collaboration agreement with BMS and our fibrosis and CNS collaboration with UCB. This was offset by collaboration and license revenue from our China collaboration with Zai Lab. We triggered a $2 million milestone payment from Zai Lab in the third quarter of 2018 for the first patient dosed in the Phase 3 FIGHT trial which is mostly reflected in deferred revenue and will be recognized as revenue over time.

    R&D expenses totaled $45 million for the quarter a 5% increase from the $43 million of our R&D expenses in the third quarter of 2017. This increase included $10.4 million in milestone payments triggered by the dosing of the first patient in the Phase 3 FIGHT trial increased clinical expenses to advance our development programs and employee compensation offset by decreased spending on preclinical programs.

    G&A expenses totaled $9.8 million for the quarter a slight increase from $9.7 million in 2017 due to increased patent, legal and consulting expenses offset by reduced personnel and other miscellaneous costs.

    Net loss for the third quarter of 2018 was $47 million or $1.37 per basic and diluted share.

    Looking ahead, we continue to expect full year 2018 net cash used in operating activities to be less than $135 million. Five Prime is revising our guidance and we now estimate ending 2018 with approximately $265 million in cash, cash equivalents and marketable securities an increase from our previous guidance of approximately $250 million.

    Also today, we filed a new shelf-registration statement on Form S3. The registration statement covers the sale of up to $250 million of our common stock. This is a good housekeeping step and we have no plans to draw from the shelf at this time.

    I will now turn the call back to Aron for closing remarks.

    Aron Knickerbocker

    Thanks Linda.

    As Bryan mentioned the key differentiator for Five Prime is our discovery platform that we use to identify novel targets and biology in immuno-oncology. Underlying this platform is our collection of thousands of extracellular proteins. These are secreted proteins or soluble forms of cell surface proteins.

    Over the years, we've built out these extracellular protein libraries and developed sophisticated ways to screen these libraries in high throughput cell-based models about physical assays and in vivo models. Our screens often leverage our extensive robotics and computing power and generate big data, which we then assess agnostically to identify the very best targets. These discoveries drive our pipeline.

    We expect to build on this momentum throughout the rest of the year and into next. We have talented committed people and we continue to push the tempo on all of our programs as we bring forward novel medicines to patients in need.

    You can see our expected milestones on Slide 22. We are well-funded and financially disciplined and we have multiple levers to fund the company including the potential for additional strategic collaborations. We regularly engage in business development discussions. I remain very confident in the future of Five Prime.

    And finally, before we open up the call for questions, I want to thank the patients and investigators participating in our clinical trials, our Five Prime employees and our strategic collaborators.

    I will now open it up to questions.

    Question-and-Answer Session

    Operator

    Thank you. [Operator Instructions] And our first question comes from Chris Shibutani with Cowen & Co. Your line is now open.

    Unidentified Analyst

    Hi. Yes. Thanks for taking the question. This is [indiscernible] on Chris Shibutani. It looks like there's lots of progress being made across the pipeline. One thing we're curious about is there's a lot of interest going on clinical development and CSF1R antagonist these days. Can you help us understand, how cabiralizumab may be differentiated from all the competition and all the other indications trial designs that are going on out there? Thank you.

    Aron Knickerbocker

    Yes. Thanks TJ. I think you've called out some of the possibilities -- variables between the programs, so there are mechanisms, there are development strategies and combinations. With respect to cabira, we selected an antibody that bound to an epitaph on CSF1 receptor which is where the two lag end binds, CSF1 and Interleukin 34 and thereby we turn off signaling through the CSF1 receptor. And it's known the TAMs depend on that signaling to proliferate and activate. So we've already shown that we can successfully deplete TAMs. We presented some of those data at ASCO this year and a poster with our colleagues at BMS.

    So mechanistically we think we have a good molecule in cabira. Secondly, we feel that we've found a dose and a schedule that's effective clinically. And so that's now being advanced in Phase 2 trials. That's the 4 milligrams per kilogram every two weeks dose. So there are of course other CSF-1R inhibitors both antibodies and small molecules. We think that cabira's profile is very attractive.

    We're also in a leading position now as being the first program to get into a randomized Phase 2 trial and the first to combine with chemotherapy. We're aiming to be hopefully first to market.

    We also selected tumor types that we think are important with respect to the infiltration of TAMs into the micro environments of pancreatic cancer being one of those of course. And that's where we're now in two Phase 2 studies with cabira but others as well. And you can see that our partners at Bristol are exploring things like renal, long and melanoma.

    So we are quite confident in the mechanism and the dosing schedule. We've already shown a signal as we announced last year in terms of clinical efficacy in a patient population and setting in which you would expect to have no activity from a checkpoint inhibitor like in vivo. And particularly as Helen mentioned in patients who are microsatellite stable and have low tumor mutation burden. But that trial then led to the Phase 2 study that's ongoing as well as other programs that are ongoing with cabira.

    Helen Collins

    I don't know that I have too much to add to that. I mean I do think that the dosing is important now. And as you know some of these other ones are being looked at Q3 and Q1 and Q4 and we really think we spent some time and we're quite confident about the Q2 dosing being important in terms of the therapeutic window of this drug.

    And then, again, just to reiterate it's the same different tumor types, so I think all we can really know in detail is our own trial and of course it's that the results you see are unequivocal. I mean the combination showed responses in a disease that had not shown responses with Io therapies. So…

    Aron Knickerbocker

    And at the level, the micro environment we do know that we change it from a tolerant -- tumor tolerant microenvironment to an inflamed more immunological active microenvironment so we see a shift in polarization from M2 type TAMs to M1 macrophages that's what we want to have happen. We see CD8 cells infiltrate the microenvironment, the T cells can carry out the attack.

    So we know that we're changing the micro environment in a positive way the gene expression also signals pro-inflammatory markers coming up in the microenvironment, patients who've been treated with this combination.

    So with that I will stop. But did that answer your question TJ?

    Unidentified Analyst

    Yes. That's great. I will hop back in the queue. Thank you.

    Aron Knickerbocker

    Thank you.

    Operator

    Thank you. And our next question comes from Jim Birchenough with Wells Fargo. Your line is now open.

    Nick Abbott

    Good afternoon. It's Nick in for Jim, this afternoon. I'd like to maybe talk a little bit about FPA150 and so the exploratory cohorts that's ongoing, it's great news that has started. So 10 patients this is really trying to establish a recommended Phase 2 dose, obviously, get some initial signal or efficacy what are you hoping to show in this exploratory cohorts?

    Aron Knickerbocker

    Thanks Nick. Helen take that.

    Helen Collins

    Yes. So I think and I'm sorry not remembering off the top of the head, the slide number you'll see that we're doing all kind of dose escalation is what we did initially and that's continuing. So that -- and there if you know, it will stop if we -- if we know or when we hit a DLT just to get a tolerability.

    We did what we're calling an exploratory because we know we're doing this at a dose that probably is lower than what will end up being our recommended Phase 2 dose. But we're taking as we're calling it a basket any patient who has a very high B7H4 score. And we're calling this a basket because we certainly know about breast ovarian, endometrial et cetera. But there are some other less common tumors that also highly over express B7H4, I don't know how public we've gone about those. So we're allowing patients like that to go on or with one of these tumors that we know about. So the point of this is really just trying to get a little bit of -- a little bit of data at some of these lower doses.

    And again, what our final recommended Phase 2 dose will be -- could be at the same dose as one of these exploratory, but will probably be higher, but this is really a chance we're hoping to get some proof of concept get some baseline on to in biopsies and be able to get earlier than we would otherwise get it just as a sense of how good is this single agent activity going to be.

    Nick Abbott

    Okay. And then for the Phase 1b, do you think they might be able to start in 1H '19 and are you considering sort of Simon 2 stage design for these cohorts to get an early tumor specific look at efficacy?

    Helen Collins

    I think you know even our cabira trial as well, we pride ourselves on being able to write these trials to be as flexible as we think we can be. So I think all of those are reasonable thoughts and that will be a balance right. I mean it's depending on how and some of that will be -- so I'm being vague on purpose because our protocols are written to be quite vague. But I think those are our expectations. I would certainly be disappointed if we didn't start out 1b in the first half of next year. How's that.

    Aron Knickerbocker

    We are in final steps of those levels. So we're making great progress this trial as I mentioned as one of those, it's gone much faster than our original timeline and I think that is reflective of a strong interests in having B7H4 antibody for these patients. But, given that we are at dose level 7 of 8, I think it's reasonable to expect that we could be into Phase 1b in the first half of the year.

    Nick Abbott

    And then maybe just a quick question on the biology. So the counter receptor is not known, what do you know about co-expression of B7H4 with other checkpoints on immune calls?

    Bryan Irving

    Are you referring to maybe you say PD-L1 expression.

    Nick Abbott

    Yes. Things like that. Exactly.

    Bryan Irving

    Yes. There's not a direct overlap. There is a subset of tumors that can co-express them, but they're clearly not often co-expressed. And we know that PD-L1 one is induced by gamma interferon. We're still trying to figure out what 784 is up regulated by that. We do think it's intriguing that it seems to be an indications where PD-L1 is not prevalent. So maybe we're hoping it will be a dominant receptor in these unique indications that are served by PD-1 blockers.

    Nick Abbott

    Sorry. These are soluble version of the receptor.

    Bryan Irving

    Yes. I think there has been reported or shared B7H4. Yes, you can't see it in the serum. It's not at extreme high. High levels in fact we thought of using that as a potential PD marker for optimal dosing. But it's infrequent enough and not exhibition levels to be able to use it for that purpose.

    Nick Abbott

    Okay. Thank you.

    Aron Knickerbocker

    Just want to add Nick that even if the tumor cell is expressing other checkpoints such as PD-L1, we still think or anybody could be active as monotherapy to ADCC components, so we recruit and case cells into the tumor and they can then attack B7H4 positive cells. So kind of two ways to win with FPA150.

    Nick Abbott

    Okay. That's very clear. Thanks.

    Aron Knickerbocker

    You are welcome.

    Operator

    Thank you. And our next question comes from Jonathan Chang with Leerink Partners. Your line is now open.

    Jonathan Chang

    Hi. Thanks for taking my questions. First question given the faster than expected progress being made in the FPA150 study, can you provide any more granularity on when in 2019 you might see initial clinical data?

    Helen Collins

    So, this is Helen. I think you heard, we're starting to enroll patients out of -- the minimally efficacious dose. And so it's reasonable to think that we'll have some data by the middle of the year. How informative that data will be hard to tell? Certainly by the end of the year, we think we should have a fair number of patients that have enrolled in the B7H4. So I know that's been kind of vague again but I think it really depends on how quickly we get data from these next couple of cohorts.

    Jonathan Chang

    Great. Thanks. Second question with the abstracts published this morning. Can talk about your view on the TIM-3 competitive landscape and how do you view your TIM-3 partner with Bristol positions. Are there meaningful points of differentiation that you need to highlight?

    Aron Knickerbocker

    Yes. Thanks Jonathan. I'll start and my colleagues may have some things to add, so our partners at Bristol are presenting a preclinical poster on the TIM-3 program. That said it is in a clinical trial now in a Phase 1/2 study with dose escalation occurring in the monotherapy portion, and then, combination will be with up OPDIVO in the Phase 2 part. And, of course, Cicero has a TIM-3 temporary program as well.

    We don't know exactly how their antibody behaves but what we know about our antibody and with our partners at Bristol. We selected it to prevent and interaction with a particular binding partner in the tumor microenvironment. So we know it does that we think that's an important binding partner. I will let Bryan comment as well on this.

    Bryan Irving

    Well, there have been at least three molecules that have been shown to interact with TIM-3. I think there's still debate in the field about which one or which ones are functionally important or relevant. One of those is Galectin 9 and other is CEACAM-1 and the other is [indiscernible]. We don't know what each of the competitors targets. Some of them are not reporting. I don't know that we've reported on the posters, so I'm not going to say what we think we're targeting. But we believe we're targeting the dominant important interaction with TIM-3.

    Jonathan Chang

    Great. Thank you. And just one last one if I may, for FPT155, how should we think about the risk of super agonism and also can you provide more color on the Phase 1 development strategy for this program?

    Aron Knickerbocker

    Yes. The risk of super agonism, yes we assess that pre-clinically and Bryan can comment on those studies.

    Bryan Irving

    There's an assay that now the FDA wants people to view with almost all T-cell modulars that actually reveal the cytokine storm potential of the TeGenero antibody, the CD28 superagonist antibody. You take PVMCs from human blood and if you quote the drug on a plate you can now reveal this activity of its presence. So we've done this assay with our molecule FPT155 and compared it to TeGenero agonist antibody, the agonist antibody definitely reveals quite high cytokine release whereas ours doesn't. But now if we add TCR simulation, we now see the expected enhancement in cytokine secretion from the T cells. So in an assay that we know is sensitive enough to reveal this super agonism, we know that our drug does not do it.

    Aron Knickerbocker

    Then, the Phase 1 strategy.

    Helen Collins

    Yes. And as far as the Phase 1 strategy, again with a novel checkpoint we have to start at a very low dose, of course that was similar to 150. We moved very quickly with 150. So hopefully we moved just as quickly with 155. I think in this case, for 155 there is going to be a much broader swath of tumors that would potentially be sensitive to this drug. I think what we're thinking about aside from obviously the dose escalation being an all tumor types is, except for those tumors that are -- the classic we really, really, really cold tumors that by virtue of how this drug works because it essentially is safe partially CTLA4 and then also this agonism that we should be able to demonstrate clearly better single agent efficacy than you would expect with something such as FTA or CTLA4 lone.

    So you can imagine those kind of tumors where maybe those drugs like that have some mild to moderate benefit head, neck at a cellular non-small cell lung cancer et cetera that this may have a more significant single agent activity. But -- and that's those are the kind of things that we'd look at in our exploratory cohorts.

    Jonathan Chang

    Thank you. That's helpful.

    Operator

    Thank you. And our next question comes from Robin Karnauskas with Citi. Your line is now open.

    Unidentified Analyst

    Hi. This is Nicole on for Robin. For this trial, can you just remind us about the IHC and ctDNA tests you were using identify the patient? And going forward, how could you also explain how they're differentiated and will you be developing its diagnostic for this indication?

    Helen Collins

    I think I got the first two questions and then -- well, first of all, there are two -- so there are two diagnostics to identify the patients. The patients all get tissue sent in and again these are newly diagnosed patients, so they should have tissue sitting around somewhere and then a blood sample sent in as long as they are positive for FGFR2b either way. So if the tissue stays positive by IHC or if the blood demonstrates amplification of FGFR2b that patients would be allowed to enroll. We do not expect complete overlap although we expect significant overlap in both of these tests. But that's how we end up with about 10% of the patient population. So the IHC being done with a Ventana and the ctDNA with PGDx.

    Aron Knickerbocker

    I think your last question is about -- whether those would be companion diagnostics, is that right?

    Unidentified Analyst

    Yes.

    Aron Knickerbocker

    Yes. So the answer is yes. That they're being developed in conjunction with bema and they would be part of the approval. And it's our strategy to have these available commercially -- bema is available commercially it would allow for patient selection again by either test.

    Helen Collins

    People do not have to be positive by both just one or the other.

    Unidentified Analyst

    Okay, great. Thank you.

    Aron Knickerbocker

    Thank you.

    Operator

    Thank you. And our next question comes from Eun Yang with Jefferies. Your line is now open.

    Alex Heller

    Hi. This is Alex Heller on for Eun. I just had two questions. For cabira, can we expect data from the Phase 2 study in pancreatic cancer in 2019? And will that be first half or second half of 2019? And then secondly for bema, is the Phase 1 data at ASCO GI solely going to be safety data or can we expect any preliminary efficacy data? Thanks.

    Aron Knickerbocker

    Okay. Alex thanks. So for cabira Bristol-Myers Squibb, our partners are running the Phase 2 trial. It's our understanding the enrollment is going well. As we mentioned they've got a number of sites, so you can see our clinicaltrials.gov, thirty nine sites are planned worldwide. Many are open. Others are opening. So we expect this trial to enroll quickly.

    We also know from our own experience in running pancreatic cancer cohorts those enrolled very quickly just because of the tremendous unmet need in pancreatic cancer and the lack of available alternatives. So we think it's reasonable that the trial could be enrolled next year by BMS. But we can't guide when that would happen or when the data would be presented. That's up to them. But we think they're doing all the right things to get it done quickly.

    And then with respect to bema and the ASCO GI presentation that we'll make, I'll turn it Helen.

    Helen Collins

    Yes. So the Phase 1 or the safety lead-in as you may recall we were not anticipating there to be any overlapping toxicity and indeed the fact that we of course come through for the pivotal as the full dose if you will of bema has demonstrated that. So we know that the point of that being that we didn't have to enroll very many patients, so I don't want to make a big deal about what efficacy data we have. This trial did not require for the Phase 1 part that the patients had to have gastric cancer nor did they have to be FGFR2 positive. But we did have some patients that had that so. Yes, we will report on what efficacy we have. But I don't want to overstate that that's a huge amount.

    Alex Heller

    Okay. Perfect. Thank you.

    Operator

    Thank you. And our next question comes from Kennen MacKay with RBC Capital Markets. Your line is now open.

    Justin Burns

    Hi. This is Justin on Kennen. I wanted to follow up on the IHC diagnostic and the FIGHT trial. I was wondering if you could discuss how this diagnostic approach differs at all from the IHC that was used in the Phase 1 trial? Thank you.

    Helen Collins

    So I think the simplest thing is to say the IHC -- we did the Phase 1 trial with an IHC and then moving forward to an actual LTD and developing the CDX. We've done extensive evaluation of -- we had over 600 patients that we screened too for our Phase 1 and also working with Ventana a very large databank of gastric cancer patients samples. So it's really by using those that we've determined where the cut off was when we looked at each score to determine where we were seeing responses and where we weren't and use that as our cutoff for our Phase 3.

    Aron Knickerbocker

    Yes. So Ventana did a lot of work to lock-in the assay on their platform that they use worldwide. What we do know is, we see a good concordance with the IHC that was used in Phase 1. So we don't expect huge discrepancies between the rates that we saw for IHC levels in the Phase 1 and what we expect going forward and the FIGHT trial and also upon commercialization at that point.

    Helen Collins

    Now, so we feel very confident about our cutoff in terms of what we need to see to get the potential for response.

    Aron Knickerbocker

    Did you also have a question about the ctDNA?

    Justin Burns

    No. It was just the IHC.

    Aron Knickerbocker

    Okay. Thanks Justin.

    Helen Collins

    So we looked at thousands of samples.

    Operator

    Thank you. And our next question comes from Eric Josephs with JPMorgan. Your line is now open.

    Eric Joseph

    Hey, guys. Thanks for taking the question. Just one on cabiralizumab, it looks as though the focus is increasing on pancreatic cancer with the Stand Up for cancer GemCaN study. I'm just curious to get your take on whether Bristol's optimism that they're communicating with [indiscernible] extends beyond pancreatic cancer. If there are whether other tumor types are potentially on the table from what they're seeing in the ongoing Phase 1 or preclinical data or pancreatic cancer is primarily the focus going forward. Thanks.

    Aron Knickerbocker

    Sure. Thanks your question Eric. Well, I mentioned the study in long renal and melanoma. That's one example. The other thing I would point out is that in the poster at ASCO, Bristol did say that the data from the ongoing study, support additional clinical investigation in pancreatic and other tumor types. But at this point we're not in a position to disclose what additional work will be conducted in other tumor types. It's not yet public, but we and Bristol remain interested in pancreatic and other cancers.

    Eric Joseph

    Is there -- give a sense of when you might be able to kind of update the street on the potential plans as for the pancreatic and other tumors types? Thanks.

    Aron Knickerbocker

    We can't guide at this point in time to just given the -- a lot of this is confidential and subject to our collaborative obligations with our partners at BMS. But when we are able to speak we'll certainly inform the street about it.

    Eric Joseph

    Great. Thanks for taking the questions.

    Aron Knickerbocker

    Thank you, Eric.

    Operator

    Thank you. And our next question comes from Steve Seedhouse with Raymond James. Your line is now open.

    Steve Seedhouse

    Thank you. So my understanding on B7H4 that it's expressed by tumor epithelial cells, but also tumor associated macrophages or expression at least might correlate with TAM Treg infiltration into tumor. So I mean in your slides you have a cartoon, you focus on sort of the tumor autonomous effects whether that's blocking ADCC or checkpoint inhibition. I'm curious to get your broader thoughts on just the complexity of the mechanism in different cell types, how solid are some of those macrophage expression data and are you looking for markers or anything in the clinical program to help you parse out the relative contributions of the microenvironment. And does that even really matter as it relates to choosing indications and sort of designing the next stage of trials?

    Bryan Irving

    We don't think we need because of the two mechanisms. But I think the more we can learn about the receptor, the better we can position in the clinical development. I should say in our preclinical mouse models we have not been able to find convincing expression of B7H4 on the infiltrating macrophages. This is consistent with a couple of reports that have been published but we've looked very carefully and we haven't found it.

    But that said, we're currently doing human analysis of human tumors to see if we can see it on the macrophages. Now you can sometimes see messenger RNA for the protein but we don't see it on the surface. So it's still a little confusing, but we are doing analysis of human tumors with the intent of looking both directly at the tumor cells and the macrophages.

    Steve Seedhouse

    Okay. Appreciate it.

    Bryan Irving

    But I guess, while PD-L1 -- just like PD-L1, we would assume that both the macrophages and the tumor could contribute to inhibition of the T cells and that by blocking it. We would relieve both methods or both modes of suppression.

    Steve Seedhouse

    Okay. That's helpful. And just apologies if this has been asked, but on the -- you mentioned possibility of specific or exploring either Io or chemo combination strategies depending on the Phase 1b data. I'm just curious if you already have specific combination mechanisms in mine based on preclinical data and if there's a specific efficacy hurdle you'd be looking for in certain patients in Phase 1b to move ahead with specific combinations?

    Helen Collins

    Yes, we have some ideas and we've done a lot of preclinical work. I think when we're looking at -- in a single arm study we definitely want to see it -- a doubling of whatever response rate of whatever tumor would be at least that would be something that we would consider at least the bar that you'd want to achieve before you move things forward. We haven't said anything any more details on that though.

    Steve Seedhouse

    Okay. Would be, I mean I guess the obvious candidates just traditional checkpoint inhibitors would be some of the Io combos you'd be considering. Is it something more novel than that?

    Bryan Irving

    Preclinically, we definitely see that that PD-1 [Technical Difficulty] going nicely with the B7H4, FPA150. So once you kill the tumor cells and initiate an immune response we would expect PD-1 to be one of the things that inhibits that. So it's may make sense as a rational combination partner for this but we also have looked at other modulators in the tumor microenvironment. So it's not just the one that we're looking at.

    Helen Collins

    And again because B7H4 does not appear to be -- much if any on normal tissues, we aren't anticipating too much in the way of toxicity which potentially would allow it to be combined with things other than PD-1. And I say that more from the point of view of the clinician, which is as you know that particularly these tumors where PD-1s aren't approved, I mean a subpopulation of triple negative breast cancer maybe that caveat. But for the other tumor types that we're looking at they aren't. And so it may be a faster pathway even if the science is there. I smile looking at Bryan but to combine with other things such as your PARP inhibitors or chemotherapy. I think it needs to be a combination always of the science. Obviously, number one but also then what the clinical need is. And how those drug turns out to be. Thank you.

    Steve Seedhouse

    Okay. Thank you. Appreciate the question.

    Aron Knickerbocker

    Thanks Steve.

    Operator

    [Operator Instructions] I am showing no further questions at this time. I would like to turn the call back over to Aron Knickerbocker, Chief Executive Officer for closing remarks.

    Aron Knickerbocker

    Okay. Well, I'd like to thank you all for joining us today and for your support of Five Prime. And we look forward to updating you on future calls. Thank you.

    Operator

    Ladies and gentlemen, thank you for your participation in today's conference. This concludes the program. And you may now disconnect. Everyone have a good day.

    SeekingAlpha

    With CCIE Data Center, can network engineers become data center gurus? | killexams.com real questions and Pass4sure dumps

    In the world of the next-generation data center, the skills that once sustained an engineer's career just aren't enough anymore. In enterprises where virtualization and cloud computing are putting new demands on the network, an engineer must know more than routing and switching.

    Cisco Systems acknowledged this trend recently when it announced its new CCIE Data Center certification program. It's a departure from some of Cisco's other advanced CCIE certifications, which focus on specific technologies like routing and switching, security or wireless. CCIE Data Center will ask network engineers to develop a relatively deep understanding across storage and server technologies as well.

    "I think the data center is becoming a discipline unto itself," said Zeus Kerravala, principal and founder of ZK Research. "If you look at the data center today, it's significantly more network-dependent than it ever has been in history."

    In turn, IT organizations are seeking network engineers who can collaborate with server and storage teams more effectively, according to Howard Hooper (CCIE #23470), an independent network engineer based in the United Kingdom.

    "It's moved on from the days of just architecting a network, where you make sure routers and switches had the correct amount of capacity and quality of service [QoS], to actually making sure you're fulfilling the requirements of the storage team and making sure your [FCoE] connectivity works within the network as well," said Hooper.

    Hooper, who plans to sign up for the beta CCIE Data Center exam, is working on a large server virtualization installation that will likely require a network built on Cisco's Nexus 7000 and Nexus 5000 switches. Running Fibre Channel over Ethernet [FCoE] on this network is requiring a lot of collaboration with the storage team.

    "I'm liaising with the storage team daily to make sure their requirements are met, the customer's requirements are met and that we come up with a solution that works between us," he said.

    CCIE Data Center: Tests the gamut of Cisco data-center technology

    The CCIE Data Center written and lab exams will test engineers on a variety of familiar networking gear, including the Catalyst 3750, the Nexus 7009 core chassis, the Nexus 5548 switch and the Nexus 2232 Fabric Extender. Beyond traditional routing and switching, the certification will test applicants on their skills with the Nexus 1000v virtual switch and its application delivery controller, the Application Control Engine (ACE).

    CCIE Data Center aspirants will also have to study up on Cisco's storage area network (SAN) switch, the MDS 92221, and the company's blade-server technology, the Unified Computing System (UCS).

    The CCIE Data Center certification will be generally available in September. Beta tests will be available from May 1 to June 15, including at Cisco Live in San Diego.

    Studying Nexus 7009 without a home lab? Yikes

    Finding time to develop skills on some of the higher-end products in the CCIE Data Center exam, particularly the Nexus 7009 and the UCS servers, will be hard for many network engineers. You can't build a home lab by buying these products on eBay because they are too new.

    "I'm lucky in the position I am in because I have access to that equipment. But I have seen a number of people asking where they can get access to it, especially for training providers," said Hooper.

    So far, Learning@Cisco hasn't provided a solid solution to this problem.

    "The components with the data center tend to be very high-end equipment, and we are building out the lab capacity ourselves," said Tejas Vashi, a product manager with Learning@Cisco. "How we're going to roll that out? We're not talking about that right now. But we want to make sure our learning partners can help address talent gaps in the industry without putting too much additional burden on them."

    Note that Cisco, and other vendors, have started experimenting with cloud-based network labs recently.

    CCIE Data Center a ploy for network engineers to take over the world?

    Cynics might say that Cisco's effort to certify network engineers as master data-center architects is a ploy to position its core customers as the key decision-makers in the data center, Kerravala said.

    "But someone's got to own this," he said. "I don't see any of the compute vendors stepping up to do this. I think Cisco has an opportunity to grab the bull by the horns and educate the market on how to build out these network-dependent data centers. That's clearly the direction the industry is going, and Cisco lives and feeds off market transitions. The shift to the cloud is a big one."

    On a less cynical note, Cisco's Vashi says, "Cisco does not introduce a career certification of any level unless we are seeing an absolute need for a job role and we see a talent gap in the industry. When hiring managers need to hire folks for a specific job role and are having trouble figuring out who can do this job, we make sure there is a certification to help people qualify and help hiring managers make decisions."

    "It is getting harder and harder to silo the different parts of the data center," said Antonella Corno, the data-center product portfolio manager for Learning@Cisco, Cisco's education division. "More and more the different teams that participate in the data center need a way to communicate and a common understanding of the technologies. There is a need for an individual that is really able to understand all those different [technologies]. They may well be more well-versed in one area versus another, but they need to be able to move with agility across all of them."

    Let us know what you think about the story; email: Shamus McGillicuddy, News Director



    Direct Download of over 5500 Certification Exams

    3COM [8 Certification Exam(s) ]
    AccessData [1 Certification Exam(s) ]
    ACFE [1 Certification Exam(s) ]
    ACI [3 Certification Exam(s) ]
    Acme-Packet [1 Certification Exam(s) ]
    ACSM [4 Certification Exam(s) ]
    ACT [1 Certification Exam(s) ]
    Admission-Tests [13 Certification Exam(s) ]
    ADOBE [93 Certification Exam(s) ]
    AFP [1 Certification Exam(s) ]
    AICPA [2 Certification Exam(s) ]
    AIIM [1 Certification Exam(s) ]
    Alcatel-Lucent [13 Certification Exam(s) ]
    Alfresco [1 Certification Exam(s) ]
    Altiris [3 Certification Exam(s) ]
    Amazon [2 Certification Exam(s) ]
    American-College [2 Certification Exam(s) ]
    Android [4 Certification Exam(s) ]
    APA [1 Certification Exam(s) ]
    APC [2 Certification Exam(s) ]
    APICS [2 Certification Exam(s) ]
    Apple [69 Certification Exam(s) ]
    AppSense [1 Certification Exam(s) ]
    APTUSC [1 Certification Exam(s) ]
    Arizona-Education [1 Certification Exam(s) ]
    ARM [1 Certification Exam(s) ]
    Aruba [6 Certification Exam(s) ]
    ASIS [2 Certification Exam(s) ]
    ASQ [3 Certification Exam(s) ]
    ASTQB [8 Certification Exam(s) ]
    Autodesk [2 Certification Exam(s) ]
    Avaya [96 Certification Exam(s) ]
    AXELOS [1 Certification Exam(s) ]
    Axis [1 Certification Exam(s) ]
    Banking [1 Certification Exam(s) ]
    BEA [5 Certification Exam(s) ]
    BICSI [2 Certification Exam(s) ]
    BlackBerry [17 Certification Exam(s) ]
    BlueCoat [2 Certification Exam(s) ]
    Brocade [4 Certification Exam(s) ]
    Business-Objects [11 Certification Exam(s) ]
    Business-Tests [4 Certification Exam(s) ]
    CA-Technologies [21 Certification Exam(s) ]
    Certification-Board [10 Certification Exam(s) ]
    Certiport [3 Certification Exam(s) ]
    CheckPoint [41 Certification Exam(s) ]
    CIDQ [1 Certification Exam(s) ]
    CIPS [4 Certification Exam(s) ]
    Cisco [318 Certification Exam(s) ]
    Citrix [47 Certification Exam(s) ]
    CIW [18 Certification Exam(s) ]
    Cloudera [10 Certification Exam(s) ]
    Cognos [19 Certification Exam(s) ]
    College-Board [2 Certification Exam(s) ]
    CompTIA [76 Certification Exam(s) ]
    ComputerAssociates [6 Certification Exam(s) ]
    Consultant [2 Certification Exam(s) ]
    Counselor [4 Certification Exam(s) ]
    CPP-Institue [2 Certification Exam(s) ]
    CPP-Institute [1 Certification Exam(s) ]
    CSP [1 Certification Exam(s) ]
    CWNA [1 Certification Exam(s) ]
    CWNP [13 Certification Exam(s) ]
    Dassault [2 Certification Exam(s) ]
    DELL [9 Certification Exam(s) ]
    DMI [1 Certification Exam(s) ]
    DRI [1 Certification Exam(s) ]
    ECCouncil [21 Certification Exam(s) ]
    ECDL [1 Certification Exam(s) ]
    EMC [129 Certification Exam(s) ]
    Enterasys [13 Certification Exam(s) ]
    Ericsson [5 Certification Exam(s) ]
    ESPA [1 Certification Exam(s) ]
    Esri [2 Certification Exam(s) ]
    ExamExpress [15 Certification Exam(s) ]
    Exin [40 Certification Exam(s) ]
    ExtremeNetworks [3 Certification Exam(s) ]
    F5-Networks [20 Certification Exam(s) ]
    FCTC [2 Certification Exam(s) ]
    Filemaker [9 Certification Exam(s) ]
    Financial [36 Certification Exam(s) ]
    Food [4 Certification Exam(s) ]
    Fortinet [12 Certification Exam(s) ]
    Foundry [6 Certification Exam(s) ]
    FSMTB [1 Certification Exam(s) ]
    Fujitsu [2 Certification Exam(s) ]
    GAQM [9 Certification Exam(s) ]
    Genesys [4 Certification Exam(s) ]
    GIAC [15 Certification Exam(s) ]
    Google [4 Certification Exam(s) ]
    GuidanceSoftware [2 Certification Exam(s) ]
    H3C [1 Certification Exam(s) ]
    HDI [9 Certification Exam(s) ]
    Healthcare [3 Certification Exam(s) ]
    HIPAA [2 Certification Exam(s) ]
    Hitachi [30 Certification Exam(s) ]
    Hortonworks [4 Certification Exam(s) ]
    Hospitality [2 Certification Exam(s) ]
    HP [746 Certification Exam(s) ]
    HR [4 Certification Exam(s) ]
    HRCI [1 Certification Exam(s) ]
    Huawei [21 Certification Exam(s) ]
    Hyperion [10 Certification Exam(s) ]
    IAAP [1 Certification Exam(s) ]
    IAHCSMM [1 Certification Exam(s) ]
    IBM [1530 Certification Exam(s) ]
    IBQH [1 Certification Exam(s) ]
    ICAI [1 Certification Exam(s) ]
    ICDL [6 Certification Exam(s) ]
    IEEE [1 Certification Exam(s) ]
    IELTS [1 Certification Exam(s) ]
    IFPUG [1 Certification Exam(s) ]
    IIA [3 Certification Exam(s) ]
    IIBA [2 Certification Exam(s) ]
    IISFA [1 Certification Exam(s) ]
    Intel [2 Certification Exam(s) ]
    IQN [1 Certification Exam(s) ]
    IRS [1 Certification Exam(s) ]
    ISA [1 Certification Exam(s) ]
    ISACA [4 Certification Exam(s) ]
    ISC2 [6 Certification Exam(s) ]
    ISEB [24 Certification Exam(s) ]
    Isilon [4 Certification Exam(s) ]
    ISM [6 Certification Exam(s) ]
    iSQI [7 Certification Exam(s) ]
    ITEC [1 Certification Exam(s) ]
    Juniper [63 Certification Exam(s) ]
    LEED [1 Certification Exam(s) ]
    Legato [5 Certification Exam(s) ]
    Liferay [1 Certification Exam(s) ]
    Logical-Operations [1 Certification Exam(s) ]
    Lotus [66 Certification Exam(s) ]
    LPI [24 Certification Exam(s) ]
    LSI [3 Certification Exam(s) ]
    Magento [3 Certification Exam(s) ]
    Maintenance [2 Certification Exam(s) ]
    McAfee [8 Certification Exam(s) ]
    McData [3 Certification Exam(s) ]
    Medical [69 Certification Exam(s) ]
    Microsoft [368 Certification Exam(s) ]
    Mile2 [2 Certification Exam(s) ]
    Military [1 Certification Exam(s) ]
    Misc [1 Certification Exam(s) ]
    Motorola [7 Certification Exam(s) ]
    mySQL [4 Certification Exam(s) ]
    NBSTSA [1 Certification Exam(s) ]
    NCEES [2 Certification Exam(s) ]
    NCIDQ [1 Certification Exam(s) ]
    NCLEX [2 Certification Exam(s) ]
    Network-General [12 Certification Exam(s) ]
    NetworkAppliance [36 Certification Exam(s) ]
    NI [1 Certification Exam(s) ]
    NIELIT [1 Certification Exam(s) ]
    Nokia [6 Certification Exam(s) ]
    Nortel [130 Certification Exam(s) ]
    Novell [37 Certification Exam(s) ]
    OMG [10 Certification Exam(s) ]
    Oracle [269 Certification Exam(s) ]
    P&C [2 Certification Exam(s) ]
    Palo-Alto [4 Certification Exam(s) ]
    PARCC [1 Certification Exam(s) ]
    PayPal [1 Certification Exam(s) ]
    Pegasystems [11 Certification Exam(s) ]
    PEOPLECERT [4 Certification Exam(s) ]
    PMI [15 Certification Exam(s) ]
    Polycom [2 Certification Exam(s) ]
    PostgreSQL-CE [1 Certification Exam(s) ]
    Prince2 [6 Certification Exam(s) ]
    PRMIA [1 Certification Exam(s) ]
    PsychCorp [1 Certification Exam(s) ]
    PTCB [2 Certification Exam(s) ]
    QAI [1 Certification Exam(s) ]
    QlikView [1 Certification Exam(s) ]
    Quality-Assurance [7 Certification Exam(s) ]
    RACC [1 Certification Exam(s) ]
    Real-Estate [1 Certification Exam(s) ]
    RedHat [8 Certification Exam(s) ]
    RES [5 Certification Exam(s) ]
    Riverbed [8 Certification Exam(s) ]
    RSA [15 Certification Exam(s) ]
    Sair [8 Certification Exam(s) ]
    Salesforce [5 Certification Exam(s) ]
    SANS [1 Certification Exam(s) ]
    SAP [98 Certification Exam(s) ]
    SASInstitute [15 Certification Exam(s) ]
    SAT [1 Certification Exam(s) ]
    SCO [10 Certification Exam(s) ]
    SCP [6 Certification Exam(s) ]
    SDI [3 Certification Exam(s) ]
    See-Beyond [1 Certification Exam(s) ]
    Siemens [1 Certification Exam(s) ]
    Snia [7 Certification Exam(s) ]
    SOA [15 Certification Exam(s) ]
    Social-Work-Board [4 Certification Exam(s) ]
    SpringSource [1 Certification Exam(s) ]
    SUN [63 Certification Exam(s) ]
    SUSE [1 Certification Exam(s) ]
    Sybase [17 Certification Exam(s) ]
    Symantec [134 Certification Exam(s) ]
    Teacher-Certification [4 Certification Exam(s) ]
    The-Open-Group [8 Certification Exam(s) ]
    TIA [3 Certification Exam(s) ]
    Tibco [18 Certification Exam(s) ]
    Trainers [3 Certification Exam(s) ]
    Trend [1 Certification Exam(s) ]
    TruSecure [1 Certification Exam(s) ]
    USMLE [1 Certification Exam(s) ]
    VCE [6 Certification Exam(s) ]
    Veeam [2 Certification Exam(s) ]
    Veritas [33 Certification Exam(s) ]
    Vmware [58 Certification Exam(s) ]
    Wonderlic [2 Certification Exam(s) ]
    Worldatwork [2 Certification Exam(s) ]
    XML-Master [3 Certification Exam(s) ]
    Zend [6 Certification Exam(s) ]





    References :


    Dropmark : http://killexams.dropmark.com/367904/11788598
    Wordpress : http://wp.me/p7SJ6L-1G5
    Dropmark-Text : http://killexams.dropmark.com/367904/12550715
    Blogspot : http://killexamsbraindump.blogspot.com/2017/12/ensure-your-success-with-this-351-080.html
    RSS Feed : http://feeds.feedburner.com/FreePass4sure351-080QuestionBank
    Box.net : https://app.box.com/s/df6ndz5ajl30ln59o73cqj6cdqtxzqe5






    View Practice Questions »

    We Make Sure Q&A work for you!

    See Entry Test Preparation   |   Project Management, English Tests Home

    Pass4sure PDFs (Pass4sure Questions and Answers), Viewable at all devices like PC Windows (all versions), Linux (All versions), Mac / iOS (iPhone/iPad and all other devices), Android (All versions). It support High Quality Printable book format. You can print and carry anywhere with you, as you like.

    Testing and Training Engine Software (Pass4sure Exam Simulator) Compatible with All Windows PC (Windows 10/9/8/7/Vista/XP/2000/98 etc). Mac (Through Wine, Virtual Windows PC, Dual boot). It prepares your test for all the topics of exam, gives you exam tips and tricks by asking tricky questions, uses latest practice quiz to train you for the real test taking experience in learning mode as well as real test mode. Provides performance graphs and training history etc.

    Read more »

    More Useful Links about 351-080

    Certification Vendors Here   |   View Exams, Latest Home

    Information Links



    References:


    [EC] Exam Questions and Answers | [EC] Brain Dumps - index.php
    [EC] Real Questions and accurate answers for exam - pass4sure-cas-biz.php
    Kill exams certification Training Exams - list.php
    Killexams Study Guides and Exam Simulator - diamondfp.php
    Pass4sure Exam Study Notes - bilgis.com.tr
    Latest Certification Exams with Exam Simulator - mardukstudios.php
    Killexams [EC] Exam Study Notes | [EC] study guides - dekhoprice.php
    Killexams [EC] Exam Study Notes | [EC] study guides - csj.php
    Killexams Exam Study Notes | study guides | QA - certification-list.php
    Real Questions and accurate answers for exam - komsilanbeagle.php
    Real exam Questions and Answers with Exam Simulators - list.php

    View Practice Questions »

    Services Overview

    We provide Pass4sure Questions and Answers and exam simulators for the candidates to prepare their exam and pass at first attempt.

    Contact Us

    As a team are working hard to provide the candidates best study material with proper guideline to face the real exam.

    Address: 15th floor, 7# building 16 Xi Si Huan.
    Telephone: +86 10 88227272
    FAX: +86 10 68179899
    Others: +301 - 0125 - 01258